Prof. Riccardo Dolcetti is a clinician scientist with MD specializations in Oncology and Clinical Immunology with >20 y research experience the areas of cancer immunology/immunotherapy and infection-associated tumours. He has been the Director of the Cancer Bio-Immunotherapy Division at the CRO-National Cancer Institute of Aviano, Italy, where he had the opportunity to perform cutting-edge science in the fields of pathogenesis and novel immune-based therapies of lymphomas and infection-driven tumours. His activity was also devoted to the clinical translation of new cancer immunotherapies and the development of diagnostic assays to improve monitoring of cancer immunotherapy responses. At the end of 2015 he relocated from Italy to Brisbane in the position of Research Chair in Cancer Medicine, Diamantina Institute, University of Queensland where he developed innovative cancer vaccines for breast cancer, melanoma and brain tumours. From November 2020, he was appointed as Head of Clinical and Translational Immunotherapy at the Peter MacCallum Cancer Centre / Victorian Comprehensive Cancer Centre a joint appointment with the University of Melbourne. He had the privilege to be the President of the Italian Society for Cancer Research in 2012-13.